NEW YORK, April 7, 2016 /PRNewswire/ -- U.S. Treasury regulation has dissuaded Pfizer from its planned merger with Ireland-based Allergan. The two companies agreed on Tuesday to terminate the deal. The tax inversion move would have benefited Pfizer's profitability and reintroduced the company to the dermatologics market. Pfizer will now consider business divestitures in order to boost its profits. Kalorama thinks that in addition to these steps, Pfizer will continue to spotlight its vaccine business, where it leads the pediatric category, according to its recent report available here.
"Continued patent expirations of important pharmaceutical products have also impacted Pfizer's revenues, necessitating an aggressive re-positioning of the company's business which has resulted in the expansion of its vaccines operation," Kalorama Publisher Bruce Carlson said in a recent blog post.
Pfizer is the world's largest pediatric vaccine company with over 6 billion in revenues, according to Vaccines 2016: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others).
On a global basis, Pfizer employs more than 78,000 people worldwide. In 2015, Pfizer reported total global sales of $48.9 billion, up 6% from the prior year, as the company continues to optimize its operations though the acquisition of complementary businesses and divestiture of operations that no longer fit its core mandate.
Prevnar was FDA-approved for use in children in 2000 in the United States, and is now approved in more than four dozen countries. The vaccine—pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein containing 4,6B,9V,14,18C,19F, and 23F)—targets the seven serotypes of pneumococcal bacteria most prevalent in the U.S., which are also among the most resistant to antibiotics and cause 80% of pneumococcal disease in infants. Pfizer has since phased out original Prevnar in favor of Prevnar 13.
In early 2015, Prevnar 13 received an indication expansion in Europe, to include the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults 18 years and older.
More information can be found in Kalorama Information's report Vaccines 2016: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments (Influenza, Cervical Cancer, Combinations, Hepatitis, Pneumococcal, MMR, Varicella, Poliovirus, HIB, Others) available at: http://www.kaloramainformation.com/redirect.asp?progid=88568&productid=9944129.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-after-allergan-merger-halt-vaccines-a-focus-for-pfizer-300247965.html
SOURCE Kalorama Information